Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)

Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)

177Lu-labeled prostate-specific membrane antigen radioligand therapy (177Lu-PSMA-RLT) is an innovative treatment approach that precisely delivers β radiation emitted by 177Lu to prostate cancer cells, causing radiation damage to the tumor cells’ DNA and thereby eliminating the tumor. At present, it...

Full description

Bibliographic Details
Main Author: Cancer Nuclear Medicine Committee of China Anti-Cancer Association, Chinese Association of Nuclear Medicine Physicians
Format: Article
Language:English
Published: Editorial Office of China Oncology 2024-07-01
Series:Zhongguo aizheng zazhi
Subjects:
|177lu-labeled prostate-specific membrane antigen radioligand therapy|prostate cancer|clinical practice|expert consensus
Online Access:http://www.china-oncology.com/fileup/1007-3639/PDF/1723077902409-554778255.pdf

Internet

http://www.china-oncology.com/fileup/1007-3639/PDF/1723077902409-554778255.pdf

Similar Items